核多聚腺苷酸结合蛋白1在肿瘤中的作用

doi:10.16352/j.issn.1001-6325.2025.06.0822

摘要/Abstract

摘要： 核多聚腺苷酸结合蛋白1(PABPN1)是目前在哺乳动物中发现的唯一存在于细胞核内的poly(A)结合蛋白。最早该蛋白在眼咽肌营养不良症(OPMD)的相关研究中被关注到,PABPN1的突变与聚集被认为是眼咽肌营养不良症的主要发病机制。近年来,在一些研究发现PABPN1在一些肿瘤组织中有异常表达,并且参与调控选择性聚腺苷酸化从而导致多种人类肿瘤的发生发展。本文简要介绍PABPN1的结构、功能,梳理近年来PABPN1与肿瘤相关的研究进展,为研究PABPN1在肿瘤发生发展中的作用及机制提供思路与方向。

关键词: 核多聚腺苷酸结合蛋白1(PABPN1), 选择性聚腺苷酸化, 肿瘤

Abstract: Nuclear polyadenosine-binding protein 1(PABPN1)is the only known polyadenosine-binding protein in the cell nucleus of mammals. The first attention was resulted from relevant research on oculopharyngeal muscular dystrophy (OPMD), where mutations and aggregation of PABPN1 were found to be the main pathogenesis of the disease. Recently, PABPN1 is found to be abnormally expressed in some tumor tissues, and confirmed to be involved in regulating selective polyadenylation, which leads to the occurrence and development of various human tumors. This article briefly introduces the structure and function of PABPN1, reviews progress of research related to PABPN1 and tumors in recent years, and provide our thought for exploring point potential pathways for future research on the role and mechanism of PABPN1 in the occurrence and development of tumors.

Key words: nuclear poly(A) binding protein 1(PABPN1), alternative polyadenylation, tumor

中图分类号:

R730

史立洲, 韩玮, 沈晓军. 核多聚腺苷酸结合蛋白1在肿瘤中的作用[J]. 基础医学与临床, 2025, 45(6): 822-828.

SHI Lizhou, HAN Wei, SHEN Xiaojun. Role of nuclear poly(A) binding protein 1 in tumors[J]. Basic & Clinical Medicine, 2025, 45(6): 822-828.

参考文献 29

[1]	Eliseeva IA, Lyabin DN, Ovchinnikov LP. Poly(A)-binding proteins: structure, domain organization, and activity regulation[J].Biochemistry (Mosc),2013,78:1377-1391. doi: 10.1134/S0006297913130014.
[2]	葛宏华.人源PABPN1 RRM结构域的结构生物学研究[D].合肥:中国科学技术大学,2008:20-21.
[3]	Huang L, Li G, Du C, et al. The polyA tail facilitates splicing of last introns with weak 3' splice sites via PABPN1[J].EMBO Rep,2023,24:e57128. doi: 10.15252/embr.202357128.
[4]	Eckmann CR, Rammelt C, Wahle E. Control of poly(A) tail length[J]. Wiley Interdiscip Rev RNA,2011,2:348-361. doi: 10.1002/wrna.56.
[5]	Jenal M, Elkon R, Loayza-Puch F, et al. The poly(A)-binding protein nuclear 1 suppresses alternative cleavage and polyadenylation sites[J]. Cell,2012,149:538-553. doi: 10.1016/j.cell.2012.03.022.
[6]	Apponi LH, Leung SW, Williams KR, et al.Loss of nuclear poly(A)-binding protein 1 causes defects in myogenesis and mRNA biogenesis[J]. Hum Mol Genet,2010,19:1058-1065. doi: 10.1093/hmg/ddp569.
[7]	Beaulieu YB, Kleinman CL, Landry-Voyer AM, et al. Polyadenylation-dependent control of long noncoding RNA expression by the poly(A)-binding protein nuclear 1[J]. PLoS Genet,2012,8:e1003078. doi: 10.1371/journal.pgen.1003078.
[8]	Ishigaki Y, Li X, Serin G, et al. Evidence for a pioneer round of mRNA translation: mRNAs subject to nonsense-mediated decay in mammalian cells are bound by CBP80 and CBP20[J]. Cell,2001,106:607-617. doi: 10.1016/s0092-8674(01)00475-5.
[9]	Zhang Y, Liu L, Qiu Q, et al. Alternative polyadenyla-tion: methods, mechanism, function, and role in cancer[J]. J Exp Clin Cancer Res,2021,40:51. doi: 10.1186/s13046-021-01852-7.
[10]	Curinha A, Oliveira Braz S, Pereira-Castro I, et al. Implications of polyadenylation in health and disease[J]. Nucleus,2014,5:508-519. doi: 10.4161/nucl.36360.
[11]	Banerjee A, Apponi LH, Pavlath GK, et al. PABPN1: molecular function and muscle disease[J]. FEBS J,2013,280:4230-4250. doi: 10.1111/febs.12294.
[12]	Xiang Y, Ye Y, Lou Y, et al. Comprehensive characterization of alternative polyadenylation in human cancer[J]. J Natl Cancer Inst,2018,110:379-389. doi: 10.1093/jnci/djx223.
[13]	Hahn S, Nesslinger NJ, Drapala RJ,et al. Castration induces autoantibody and T cell responses that correlate with inferior outcomes in an androgen-dependent murine tumor model[J]. Int J Cancer,2009,125:2871-2878. doi: 10.1002/ijc.24673.
[14]	Sáez-Martínez P, Porcel-Pastrana F, Montero-Hidalgo AJ, et al. Dysregulation of RNA-exosome machinery is directly linked to major cancer hallmarks in prostate cancer: Oncogenic role of PABPN1[J]. Cancer Lett,2024,584:216604. doi: 10.1016/j.canlet.2023.216604.
[15]	Zhu D, Singh S, Chen X, et al. The landscape of chimeric RNAs in bladder urothelial carcinoma[J]. Int J Biochem Cell Biol,2019,110:50-58. doi: 10.1016/j.biocel.2019.02.007.
[16]	Chen L, Dong W, Zhou M,et al. PABPN1 regulates mRNA alternative polyadenylation to inhibit bladder cancer progression[J]. Cell Biosci,2023,13:45. doi: 10.1186/s13578-023-00997-6.
[17]	Xiong M, Liu C, Li W, et al. PABPN1 promotes clear cell renal cell carcinoma progression by suppressing the alternative polyadenylation of SGPL1 and CREG1[J]. Carcinogenesis,2023,44:576-586. doi: 10.1093/carcin/bgad049.
[18]	程波.舒尼替尼通过激活PABPN1/TRSM/AR/HIF-2α信号通路促进肾透明细胞癌血管拟态形成[D].广州:南方医科大学,2022:Ⅱ-Ⅲ.
[19]	Wang L, Lang GT, Xue MZ, et al. Dissecting the heterogeneity of the alternative polyadenylation profiles in triple-negative breast cancers[J]. Theranostics,2020,10:10531-10547. doi: 10.7150/thno.40944.
[20]	Fang F, Guo C, Zheng W, et al. Exosome-mediated transfer of miR-1323 from cancer-associated fibroblasts confers radioresistance of C33A cells by targeting PABPN1 and activating Wnt/β-catenin signaling pathway in cervical cancer[J]. Reprod Sci,2022,29:1809-1821. doi: 10.1007/s43032-021-00820-y.
[21]	Ichinose J, Watanabe K, Sano A, et al. Alternative polyadenylation is associated with lower expression of PABPN1 and poor prognosis in non-small cell lung cancer[J]. Cancer Sci,2014,105:1135-1141. doi: 10.1111/cas.12472.
[22]	Zhou L, Wu Y, Xin L,et al. Development of RNA binding proteins expression signature for prognosis prediction in gastric cancer patients[J]. Am J Transl Res,2020,12:6775-6792.
[23]	鄢雯, 李囡, 古同男, 等. 从GEO数据库筛选结肠癌差异关键基因及验证[J]. 基础医学与临床, 2023, 43: 1685-1692.
[24]	Wang QH, Yan PC, Shi LZ, et al. PABPN1 functions as a predictive biomarker in colorectal carcinoma[J]. Mol Biol Rep,2023,51:40. doi: 10.1007/s11033-023-08936-x.
[25]	Zhao A, Liu Y. Propofol suppresses colorectal cancer development by the circ-PABPN1/miR-638/SRSF1 axis[J].Anal Biochem,2021,631:114354. doi: 10.1016/j.ab.2021.114354.
[26]	Zhen N, Zhu J, Mao S, et al. Alternative splicing of lncRNAs from SNHG family alters snoRNA expression and induces chemoresistance in hepatoblastoma[J].Cell Mol Gastroenterol Hepatol,2023,16:735-755. doi: 10.1016/j.jcmgh.2023.07.007.
[27]	Ohshima K, Kanto K, Hatakeyama K, et al. Exosome-mediated extracellular release of polyadenylate-binding protein 1 in human metastatic duodenal cancer cells[J]. Proteomics,2014,14:2297-2306. doi: 10.1002/pmic.201300477.
[28]	Kavoosi S, Shahraki A, Sheervalilou R. Identification of microRNA-mRNA regulatory networks with therapeu-tic values in Alzheimer's disease by bioinformatics analysis[J]. J Alzheimers Dis,2024,98:671-689. doi: 10.3233/JAD-230966.
[29]	Zhang L, Wang D, Han X, et al. Novel read-through fusion transcript Bcl2l2-Pabpn1 in glioblastoma cells[J]. J Cell Mol Med,2022,26:4686-4697. doi: 10.1111/jcmm.17481.